Table 2 Disease-free survival and overall survival comparisons between treatment arms (efficacy cohort [N = 40])

From: A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma

Survivala

Disease-free survival (months)

 

Overall survival (months)

Arm

Median follow-up (mo)

Events

Median (95% CI)

HR (95% CI) p value

Events

Median (95% CI)

HR (95% CI) p value

Cy-GVAX (n = 16)

23.1

12

13.90 (5.59, NR)

Ref.

0.92 (0.42–2.02) p = 0.829

12

23.59 (13.27, NR)

Ref.

0.90 (0.38–2.14) p = 0.813

Cy-GVAX PD-1 (n = 14)

26.1

13

14.98 (7.95, 44.09)

1.09 (0.50–2.40) p = 0.829

Ref.

11

27.01 (20.76, NR)

1.11 (0.47–2.63) p = 0.813

Ref.

Cy-GVAX PD-1 CD137 (n = 10)

31.6

6

33.51 (16.76, NR)

0.55 (0.21–1.49) p = 0.242

0.51 (0.19-1.35) p = 0.173

4

35.55 (17.74, NR)

0.59 (0.18–1.91) p = 0.377

0.53 (0.17–1.67) p = 0.279

  1. aSurvival measured from date of first [neoadjuvant] study treatment; cox regression utilized. NR not reportable.
Back to article page